Date: 2015-09-10
Type of information: Collaboration agreement
Compound: Watson Health Cloud
Company: Teva Pharmaceuticals (Israel) IBM Watson Health (USA - MA)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism: Watson is a cognitive computing platform that represents a new era of computing based on its ability to interact in natural language, process vast amounts of Big Data to uncover patterns and insights, and learn from each interaction. The system, delivered through the cloud, analyzes high volumes of data and complex questions posed in natural language and proposes evidence-based answers. Watson is continuously gaining in value and knowledge over time, from previous interactions. In January 2014 , IBM launched the IBM Watson unit, a business dedicated to developing and commercializing cloud-delivered cognitive computing technologies. The move signified a strategic shift by IBM to deliver a new class of software, services and apps that improves by learning, and discovers insights from massive amounts of Big Data. As part of the unit, the company has increased the number and diversity of cognitive computing services delivered to its partners, adding new beta Watson services in February 2015 , and scalable deep learning APIs with the acquisition of AlchemyAPI in March 2015 . In April 2015 , the company continued to build on its strengths in cognitive computing, analytics, security and cloud with the launch of IBM Watson Health and the Watson Health Cloud platform. The new unit will help improve the ability of doctors, researchers and insurers to innovate by surfacing new insights from the massive amount of personal health data being created daily. The Watson Health Cloud allows this information to be anonymized, shared and combined with a dynamic and constantly growing aggregated view of clinical, research and social health data that clients choose to share.
Disease:
Details: * On September 10, 2015, IBM Watson Health and Teva Pharmaceutical Industries announced that Teva has been selected as its first Foundational Life Sciences Partner for the Watson Health Cloud. As part of this new strategic partnership, Teva becomes the first global pharmaceutical company to tap the power of the Watson Health Cloud to benefit patients and healthcare providers across geographies. Teva has chosen the IBM Watson Health Cloud as a preferred global technology platform and aims to build solutions designed to help millions of individuals worldwide with complex and chronic conditions such as asthma, pain, migraine and neurodegenerative diseases. In addition, a joint Teva-IBM Research team will deploy Big Data and machine learning technology to create disease models and advanced therapeutic solutions. Teva will work with IBM on long-range platform and solutions development, with experts collaborating to enhance IBM Watson Health Cloud capabilities and explore synergies with existing Watson Health ecosystem partners. The company expects to develop solutions designed to collect and analyze real world evidence, draw powerful insights and inform a variety of initiatives such as reducing drug misuse or increasing prescribed medication adherence. IBM\'s Global Business Services will work closely with a Teva Analytics team to assess the data and the analytics model requirements for the Real World Evidence e-health solution.
Financial terms:
Latest news:
